<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Belantamab mafodotin (United States: Withdrawn from market): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Belantamab mafodotin (United States: Withdrawn from market): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Belantamab mafodotin (United States: Withdrawn from market): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="129247" href="/d/html/129247.html" rel="external">see "Belantamab mafodotin (United States: Withdrawn from market): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F57513461"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Blenrep Biologic License Application Withdrawn</span>
<span class="collapsible-date">November 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">GlaxoSmithKline has initiated the process for voluntary withdrawal of the Biologic License Application for Blenrep (belantamab mafodotin-blmf) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The confirmatory randomized DREAMM-3 phase 3 trial of belantamab mafodotin monotherapy versus PomDex (pomalidomide and dexamethasone) in patients with relapsed or refractory multiple myeloma did not meet its primary end point of superior progression-free survival. GlaxoSmithKline has stopped new patient enrollment into the Blenrep REMS. To ensure patients who are currently deriving clinical benefit continue to have access to Blenrep, GlaxoSmithKline will be opening a compassionate use program.</p>
<p style="text-indent:0em;">Further information may be found at https://www.blenrep.com/content/dam/cf-pharma/dsa-blenrepv3/en_US/pdf/Blenrep-(belantamab-mafodotin-blmf)DearHCPLetterNov2022.pdf.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F54712326"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Ocular toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Belantamab mafodotin caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes. Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold belantamab mafodotin until improvement and resume, or permanently discontinue, based on severity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Restricted access</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Because of the risk of ocular toxicity, belantamab mafodotin is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54730030"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Blenrep</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54712329"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-BCMA;</li>
<li>
                        Antineoplastic Agent, Antibody Drug Conjugate;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F54745585"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Perform ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening ocular symptoms. Baseline examinations should be done within 3 weeks prior to the first dose; perform subsequent examinations at least 1 week after the previous dose and within 2 weeks prior to the next dose. Patients should use preservative-free lubricant eye drops at least 4 times a day, starting with the initial infusion and continuing until the end of therapy, and avoid contact lenses unless otherwise directed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1c12cde-98c7-41e9-80b8-0893e9934cc7">Multiple myeloma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed/refractory: IV: </b>2.5 mg/kg (based on actual body weight) once every 3 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31859245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31859245'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> A confirmatory phase 3 trial in patients with relapsed or refractory multiple myeloma comparing belantamab mafodotin to pomalidimide and dexamethasone did not demonstrate a clinical benefit for belantamab mafodotin; due to the trial results, the manufacturer is voluntarily withdrawing belantamab mafodotin from the market.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54745587"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Renal function may be estimated by the Modification of Diet in Renal Disease (MDRD) equation.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 30 to 89 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been established).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease, not on dialysis or requiring dialysis (eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>): There are no dosage adjustments provided in the manufacturer's labeling (has not been established).</p></div>
<div class="block doha drugH1Div" id="F54745588"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin ≤ ULN and AST &gt; ULN or total bilirubin 1 to ≤1.5 times ULN and any AST): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment (total bilirubin &gt;1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been established).</p></div>
<div class="block doo drugH1Div" id="F54745589"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>). <b>Note:</b> Belantamab mafodotin dosing is based on actual body weight (according to the prescribing information).</p></div>
<div class="block dot drugH1Div" id="F54745656"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">Belantamab Mafodotin Dosage Reduction Levels for Adverse Reactions</caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Dose reduction level</p></th>
<th align="center">
<p style="text-indent:0em;">Belantamab mafodotin dose reduction schedule</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Usual (initial dose)</p></td>
<td align="center">
<p style="text-indent:0em;">2.5 mg/kg once every 3 weeks</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">1.9 mg/kg once every 3 weeks</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">If unable to tolerate 1.9 mg/kg once every 3 weeks, discontinue belantamab mafodotin.</p></td></tr></tbody></table>
<p style="text-indent:0em;">For corneal adverse reactions, determine the recommended dosage modification based on the worst finding in the worst affected eye; worst finding should be based on either a corneal examination finding or a change in visual acuity per the Keratopathy and Visual Acuity (KVA) scale.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">Belantamab Mafodotin Dosage Modifications for Adverse Reactions</caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="2">
<p style="text-indent:0em;">Corneal adverse reaction (per KVA scale)</p></th>
<th align="center">
<p style="text-indent:0em;">Recommended dosage modification</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Changes in visual acuity due to treatment-related corneal findings.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">Corneal examination finding(s): Mild superficial keratopathy (documented worsening from baseline), with or without symptoms.</p>
<p style="text-indent:0em;">Change in best corrected visual acuity (BCVA)<sup>a</sup>: Decline from baseline of 1 line on Snellen Visual Acuity.</p></td>
<td align="center">
<p style="text-indent:0em;">Continue belantamab mafodotin at the current dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Corneal examination finding(s): Moderate superficial keratopathy with or without patchy microcyst-like deposits, subepithelial haze (peripheral), or a new peripheral stromal opacity.</p>
<p style="text-indent:0em;">Change in BCVA<sup>a</sup>: Decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200.</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold belantamab mafodotin until improvement in both corneal examination findings and change in BCVA to ≤ grade 1, then resume at the same dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Corneal examination finding(s): Severe superficial keratopathy with or without diffuse microcyst-like deposits, subepithelial haze (central), or a new central stromal opacity.</p>
<p style="text-indent:0em;">Change in BCVA<sub>a</sub>: Decline from baseline by &gt;3 lines on Snellen Visual Acuity and not worse than 20/2000.</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold belantamab mafodotin until improvement in both corneal examination findings and change in BCVA to ≤ grade 1, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Corneal examination finding(s): Corneal epithelial defect such as corneal ulcers.</p>
<p style="text-indent:0em;">Change in BCVA<sup>a</sup>: Snellen Visual Acuity worse than 20/200.</p></td>
<td align="center">
<p style="text-indent:0em;">Consider permanent discontinuation. If continuing treatment, withhold belantamab mafodotin until improvement in both corneal examination findings and change in BCVA to ≤ grade 1, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<b>Other Adverse Reactions</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Adverse reaction</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>Severity</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>Recommended dosage modifications</b></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Platelets 25,000/mm<sup>3</sup> to &lt;50,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Consider withholding belantamab mafodotin and/or reducing the dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Platelets &lt;25,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Withhold belantamab mafodotin until platelet count improves to ≤ grade 3. Consider resuming at a reduced dose.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Infusion-related reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2 (moderate) or grade 3 (severe)</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt belantamab mafodotin infusion and provide supportive care. Once symptoms resolve, resume at a lower infusion rate (reduce the infusion rate by at least 50%). Administer premedication for all subsequent infusions.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4 (life threatening)</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue belantamab mafodotin and provide emergency care.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold belantamab mafodotin until improvement to ≤ grade 1. Consider resuming at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Consider permanent belantamab mafodotin discontinuation. If continuing treatment, withhold belantamab mafodotin until improvement to ≤ grade 1 and resume at a reduced dose.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F54745586"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55456314"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombocytopenia</b> occurred in the majority of patients. Grade 2, 3, and 4 events were common. Thrombocytopenia may warrant dose reduction and/or therapy interruption or discontinuation, depending on severity. Grade 3 to 4 bleeding events have also been reported in a small percentage of patients, including rare cases of fatal cerebral hemorrhage. <b>Lymphocytopenia</b>, <b>decreased hemoglobin</b>, and <b>decreased neutrophils</b> have also been commonly reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism is unknown, but it has been suggested that thrombocytopenia is the result of apoptosis of megakaryocyte progenitor cells induced by the nonspecific uptake of the antibody drug conjugate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32712806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32712806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Thrombocytopenia: Intermediate; median time to onset of the first thrombocytopenic events was ~27 days.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reaction</b> occurred commonly during therapy. Reactions are usually grade 1 or 2, but severe events may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31859245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31859245'])">Ref</a></span>). Treatment interruption or permanent discontinuation may be warranted, depending on severity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; most often occurred with the first infusion, though reactions have occurred with the second infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31859245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31859245'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Belantamab mafodotin may cause changes in the corneal epithelium leading to <b>ocular toxicity</b>, including <b>severe vision loss</b> and <b>corneal ulcer</b> (ulcerative keratitis and infective keratitis)<b>. </b>Commonly reported ocular events include <b>blurred vision</b>, <b>dry eye syndrome</b>, <b>epithelial keratopathy</b> and clinically significant <b>decreased visual acuity</b>. Approximately one-third of patients had both ocular symptoms and visual acuity changes. Driving and reading may be difficult due to visual acuity changes; use caution when driving or operating machinery. Other less frequently reported ocular events include <b>eye irritation</b> and <b>photophobia</b>. Ocular events commonly lead to permanent discontinuation or dose interruptions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31859245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31859245'])">Ref</a></span>). <b>Secondary cataracts</b>, requiring surgical removal, and<b></b>
<b>increased intraocular pressure</b> have also been reported postmarketing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32107339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32107339'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism of corneal events unknown but may be related to nonspecific uptake of the antibody-drug conjugate into actively dividing basal corneal epithelial cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32712806','lexi-content-ref-31859245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32712806','lexi-content-ref-31859245'])">Ref</a></span>)<b>. </b>Belantamab mafodotin enters the cornea via the vascularized region of the limbus or the tear film, becomes internalized by these corneal epithelial cells, thereby initiating apoptosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32712806','lexi-content-ref-31859245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32712806','lexi-content-ref-31859245'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most keratopathy events developed within the first 2 treatment cycles. The median time to onset of corneal epithelium changes has been reported as 37 days with a median time to resolution of 86.5 days for the first event, including those with and without dosage modifications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32712806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32712806'])">Ref</a></span>). In patients with decreased visual acuity, median time to resolution was 22 days (range: 7 days to 4.2 months).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54730283"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (43%), decreased serum potassium (20%), decreased serum sodium (21%), increased gamma-glutamyl transferase (25%), increased serum glucose (38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (13%), decreased appetite (12%), diarrhea (13%; grades 3/4: 1%), nausea (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (32%; grades 3/4: 18%), decreased neutrophils (28%; grades 3/4: 9%), lymphocytopenia (49%; grades 3/4: 22%), thrombocytopenia (62%; grades 3/4: 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (26%), increased serum aspartate aminotransferase (57%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (≤20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (12%), asthenia (≤20%), back pain (11%), increased creatine phosphokinase in blood specimen (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Decreased visual acuity [53%], dry eye syndrome [14%], epithelial keratopathy [71%]), ocular toxicity (including blurred vision [22%]</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (22%), infusion related reaction (21%; severe infusion related reaction: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (&lt;10%), hypercalcemia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation (&lt;10%), keratitis (infective keratitis and ulcerative keratitis: &lt;10%), photophobia (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal ulcer, severe vision loss</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Ophthalmic: Increased intraocular pressure (Warcel 2020), secondary cataract (Warcel 2020)</p></div>
<div class="block coi drugH1Div" id="F54712332"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F54745558"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F54730031"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Blenrep: Belantamab mafodotin-blmf 100 mg (1 ea) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F54730029"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54783497"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Blenrep Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $10,591.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F57605009"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">For patients receiving belantamab mafodotin prior to the market withdrawal, continued access will be available via a compassionate use program; compassionate use enrollment information will be provided directly to prescribers enrolled in the REMS program. Belantamab mafodotin will continue to be available while patients are being transitioned to the compassionate use program.</p></div>
<div class="block adm drugH1Div" id="F54745692"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse over ~30 minutes using an infusion set made of PVC or polyolefin. Although not required, a polyethersulfone-based filter (0.2 micron) may be used. Do not administer with any other medications. If refrigerated, allow the diluted solution to equilibrate to room temperature prior to administration; solution must be infused within 6 hours after removal from refrigeration (including infusion time). Monitor for infusion-related reactions.</p></div>
<div class="block hazard drugH1Div" id="F54745560"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F54741959"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F761158s006lbl.pdf%23page%3D22&amp;token=d%2FCTJ1lvsXrYqtQkgRWBEX3QuKZZ7Vccc0qT6h2vyCeDYKJA3gRa7dqrDus1XxxkH9kf7sSXvkZe%2FV7qEoDnVBPWxthZ6WBCpsisvEZhf4xZqRJj20Nrp9OhjYCxOxUW&amp;TOPIC_ID=129194" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761158s006lbl.pdf#page=22</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F54712331"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed or refractory: </b>Treatment of relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> A confirmatory phase 3 trial in patients with relapsed or refractory multiple myeloma comparing belantamab mafodotin to pomalidimide and dexamethasone did not demonstrate a clinical benefit for belantamab mafodotin; due to the trial results, the manufacturer is voluntarily withdrawing belantamab mafodotin from the market.</p></div>
<div class="block mst drugH1Div" id="F54741957"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Belantamab mafodotin may be confused with belimumab, belinostat, blinatumomab, brentuximab vedotin, burosumab, enfortumab vedotin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54750504"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OATP1B1/1B3 (SLCO1B1/1B3)</p></div>
<div class="block dri drugH1Div" id="F54750501"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54741964"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 4 months after the last belantamab mafodotin dose. Patients with partners who could become pregnant should use effective contraception during therapy and for 6 months after the last belantamab mafodotin dose.</p></div>
<div class="block pri drugH1Div" id="F54741963"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, in utero exposure to belantamab mafodotin may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F54741965"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if belantamab mafodotin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 3 months after the last belantamab mafodotin dose.</p></div>
<div class="block mop drugH1Div" id="F54745695"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC at baseline and during treatment as clinically necessary. Evaluate pregnancy status prior to therapy initiation in females of reproductive potential. Perform ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening ocular symptoms; baseline examinations should be done within 3 weeks prior to the first dose; perform subsequent examinations at least 1 week after the previous dose and within 2 weeks prior to the next dose. Monitor for bleeding events and for signs/symptoms of infusion-related reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs) prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54745563"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Belantamab mafodotin is an afucosylated, humanized antibody-drug conjugate directed against B-cell maturation antigen (BCMA); BCMA is expressed on multiple myeloma cells but is mostly absent on naive and memory B cells (Lonial 2020). The antibody is conjugated by a protease-resistant maleimidocaproyl linker to microtubule-disrupting monomethyl auristatin F (MMAF). After binding to BCMA, belantamab mafodotin is internalized and MMAF is released via proteolytic cleavage, resulting in cell cycle arrest and apoptosis. In addition to MMAF-induced apoptosis, belantamab mafodotin causes tumor cell lysis through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.</p></div>
<div class="block phk drugH1Div" id="F54745567"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Median time to first response: 1.4 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Most patients had a duration of response of ≥6 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 11 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: The monoclonal antibody is expected to be metabolized into small peptides and individual amino acids by catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 14 days (at steady state); 12 days (after first dose).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Shortly after the end of the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: 0.7 L/day (at steady state).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522159"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Blenrep</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Blenrep.1">
<a name="Blenrep.1"></a>Blenrep (belantamab mafodotin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32712806">
<a name="32712806"></a>Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. <i>Ophthalmol Ther</i>. 2020;9(4):889-911. doi:10.1007/s40123-020-00280-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/32712806/pubmed" id="32712806" target="_blank">32712806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31859245">
<a name="31859245"></a>Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncol</i>. 2020;21(2):207-221. doi:10.1016/S1470-2045(19)30788-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/31859245/pubmed" id="31859245" target="_blank">31859245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32107339">
<a name="32107339"></a>Popat R, Warcel D, O'Nions J, et al. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. <i>Haematologica</i>. 2020;105(5):e261-e263. doi:10.3324/haematol.2019.235937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/32107339/pubmed" id="32107339" target="_blank">32107339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belantamab-mafodotin-united-states-withdrawn-from-market-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed June 1, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 129194 Version 61.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
